Clinical experiences with molecular targeted therapy in lung cancer in China

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-7714|6|4|379-384

ISSN： 1759-7706

Source： Thoracic Cancer, Vol.6, Iss.4, 2015-07, pp. : 379-384

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non‐small cell lung cancer

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 99-104

John Wiley & Sons Inc

Access to resources Recommend Favorite

Spatial intra‐tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co‐clinical cancer studies

By  

EMBO Molecular Medicine, Vol. 7, Iss. 9, 2015-09 ,pp. : 1087-1089

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Prevalence and clinical characteristics of primary Sjogren's syndrome patients with lung cancer: An analysis of ten cases in China and literature review

By  

Thoracic Cancer, Vol. 6, Iss. 4, 2015-07 ,pp. : 475-479

John Wiley & Sons Inc

Access to resources Recommend Favorite

Current small cell lung cancer treatment in China

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 233-238

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multicentric retrospective analysis of platinum‐pemetrexed regimens as first‐line therapy in non‐squamous non‐small cell lung cancer patients: A “snapshot” from clinical practice

By  

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 241-252

John Wiley & Sons Inc

Access to resources Recommend Favorite